| Name | Title | Contact Details |
|---|---|---|
Jinhee Chang |
Intellectual Property Counsel | Profile |
Fred Medick |
General Counsel | Profile |
Aviva Gilbert |
Assistant General Counsel, Senior | Profile |
Yan Qi |
Director and Assistant General Counsel, Platforms | Profile |
Sarah Tully |
Director and Assistant General Counsel | Profile |
Loyal is part of Cellular Longevity, a company working to develop the first drugs explicitly intended to extend healthspan and lifespan — first in dogs, and then in humans, too. By quantifying and controlling the mechanisms of aging, we hope to delay the onset and reduce the severity of age-related diseases, which means more, healthier years for both species. At Loyal, our first products to market are focused on longevity and healthspan in dogs. Join us in our mission to help dogs everywhere.
Axogen is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. We are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or discontinuity to peripheral nerves by providing innovative, clinically proven and economically effective repair solutions for surgeons and health care providers. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain. Axogen`s comprehensive portfolio of products focuses on helping patients touch, run, feel, kiss, smile and hug—some of the many things healthy peripheral nerves allow us to do.
Fytokem Products Inc. is a Saskatoon, SK-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
GlobeImmune is a Louisville, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Spruce is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Our wholly-owned product candidate, tildacerfont, is a CRF1 receptor antagonist currently in late-stage trials in adult patients with classic congenital adrenal hyperplasia (CAH), with a planned Phase 2 trial in pediatric classic CAH. We aim to advance the treatment paradigm for classic CAH with a well-tolerated, non-steroidal approach designed to offer markedly improved disease control and reduced steroid burden for patients. Tildacerfont may also benefit patients with other disorders characterized by elevated levels of or hyperresponsiveness to adrenocorticotropic hormone (ACTH), a hormone involved in the production of cortisol, including a rare form of polycystic ovary syndrome (PCOS).